Literature DB >> 15696121

Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion.

Shirley Chen1, Mario M Leitao, Carmen Tornos, Robert A Soslow.   

Abstract

Stage I, low-grade endometrioid and mucinous ovarian carcinomas have an excellent prognosis. Published data have suggested that destructive stromal invasion, a relatively uncommon finding in these tumors, is a poor prognostic factor. We investigated this by studying all FIGO stage I, grades 1 and 2 (of 3) endometrioid and mucinous ovarian carcinomas that were surgically staged at the Memorial Sloan-Kettering Cancer Center from 1980 to 2000. We undertook a careful review of all available slides using current diagnostic criteria and correlated histopathologic indices with clinical outcome data. Cases studied included 13 endometrioid ovarian carcinomas (stage IA, eight; stage IC, five) and six intestinal mucinous ovarian carcinomas (stage IA, three; stage IC, three). All of the tumors contained areas of expansile invasion, greater than that acceptable for microinvasion, and were thus diagnosed as carcinomas instead of borderline tumors. Nevertheless, nearly all demonstrated borderline tumor (noninvasive) components. Six tumors contained at least one focus of destructive stromal invasion (two endometrioid and four mucinous ovarian carcinomas). Four additional cases showed a focus suspicious for but not diagnostic of destructive invasion ('indeterminate for destructive invasion') (two endometrioid and two mucinous ovarian carcinomas). Follow-up data were available for 17 patients. The median follow-up was 81 months (range, 9-161 months). In all, 14 patients were alive with no evidence of disease (expansile invasion alone, eight; destructive stromal invasion, four; and indeterminate for destructive invasion, two). Three patients died of their disease (destructive stromal invasion, two; and indeterminate for destructive invasion, one). The size, number, and nuclear grade of destructive stromal invasion foci did not appear to have an impact on survival in this relatively limited number of patients. Outcome data in patients with stage I, low-grade endometrioid and mucinous ovarian carcinomas without destructive stromal invasion indicate that these tumors have a very limited malignant potential. The literature has not documented recurrences in this setting when the staging has been complete, the sampling adequate, and the cytologic features no more than grade 2, and metastasis to the ovary has been excluded. In contrast, carcinomas harboring even limited foci of destructive stromal invasion, although frequently cured surgically, can pursue a malignant clinical course.

Entities:  

Mesh:

Year:  2005        PMID: 15696121     DOI: 10.1038/modpathol.3800366

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

Review 1.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

2.  Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.

Authors:  Melissa K McConechy; Jiarui Ding; Janine Senz; Winnie Yang; Nataliya Melnyk; Alicia A Tone; Leah M Prentice; Kimberly C Wiegand; Jessica N McAlpine; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman
Journal:  Mod Pathol       Date:  2013-06-14       Impact factor: 7.842

3.  GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.

Authors:  Tzu-Chi Lin; Syue-Ting Chen; Min-Chuan Huang; John Huang; Chia-Lang Hsu; Hsueh-Fen Juan; Ho-Hsiung Lin; Chi-Hau Chen
Journal:  Oncotarget       Date:  2017-06-27

Review 4.  EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.

Authors:  Jill K Alldredge; Ramez N Eskander
Journal:  Gynecol Oncol Res Pract       Date:  2017-10-31

5.  Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples.

Authors:  Kohei Nakamura; Kentaro Nakayama; Masako Ishikawa; Toshiko Minamoto; Tomoka Ishibashi; Emi Sato; Kaori Sanuki; Hitomi Yamashita; Ruriko Ono; Kouji Iida; Razia Sultana; Mohammad Mahmud Hossain; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Oncol Lett       Date:  2018-05-03       Impact factor: 2.967

6.  Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas.

Authors:  Toru Hachisuga; Midori Murakami; Hiroshi Harada; Taeko Ueda; Tomoko Kurita; Seiji Kagami; Kiyoshi Yoshino; Ryosuke Tajiri; Masanori Hisaoka
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

7.  Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Authors:  Bethany M Barnes; Louisa Nelson; Anthony Tighe; George J Burghel; I-Hsuan Lin; Sudha Desai; Joanne C McGrail; Robert D Morgan; Stephen S Taylor
Journal:  Genome Med       Date:  2021-09-01       Impact factor: 11.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.